Systemic Therapy

Johns Hopkins Medical Institution

Researchers at The Johns Hopkins Greenberg Bladder Cancer Institute are actively developing and evaluating new medications with the potential to treat bladder cancer. Our physician scientists direct and participate in numerous clinical trials related to bladder cancer.

Noah Hahn, associate professor of urology and oncology, is directing a phase II clinical trial of the investigational medication dovitinib in bladder cancer patients who have relapsed after treatment with the bacterial therapy BCG, who have mutations to the FGFR3 gene, and who are ineligible or do not wish to have bladder cancer removal surgery. Dovitinib binds to and inhibits FGFR3, which may hinder tumor cell proliferation and induce tumor cell death.

Other ongoing studies include trials of the drugs instiladrin; DN24-02; HS-410, a vaccine derived from irradiated bladder cancer cells; erlotinib hydrochloride, a drug that may stop the growth of tumor cells by blocking some enzymes needed for cell growth; mocetinostat; and novel combinations of existing chemotherapy drugs.